NEW YORK – Twist Bioscience said on Wednesday it has partnered with Poland's Pure Biologics on phage display libraries to accelerate antibody-based drug discovery.
Under the terms of their agreement, Twist's biopharma division will grant Pure Biologics access to select synthetic antibody phage display libraries. The companies will work together to discover, validate, and optimize new antibody candidates against useful targets for immunoncology applications.
Pure Biologics will pay Twist annual technology access fees in addition to future payments for preclinical, clinical, and commercial milestones for any antibodies resulting from the collaboration. Other financial details were not disclosed.
"We look forward to augmenting Pure Biologics' immunoncology pipeline with first-in-class bispecific antibodies identified and designed using our robust discovery and optimization engine," Twist CEO and Cofounder Emily Leproust said in a statement. "Highly selective, potent bispecific antibodies that bind to multiple targets have the potential to change the way cancer is treated in the future."
South San Francisco, California-based Twist signed a phage display library access and antibody development deal with Takeda Pharmaceutical Company in July 2020.